Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P68 | DOI: 10.1530/endoabs.35.P68

1European Medical Research Institute by Pharmaserve-Lilly SACI, Athens, Greece; 2Laboratory for Research of the Musculoskeletal System, ‘KAT’ Hospital, Athens, Greece; 3Private Medical Office, Pyrgos, Greece; 43rd Orthopedics Clinic, University of Thessaloniki, ‘Papageorgiou’ General hospital, Thessaloniki, Greece.


Purpose: Extended Forsteo Observational Study (ExFOS), a multinational, non-interventional, prospective, observational study to evaluate fracture outcomes, back pain, compliance and health-related quality of life in osteoporotic male and female patients treated with teriparatide (TPTD), has followed European Forsteo Observational Study (EFOS) on postmenopausal women, aiming to provide more data on the effect of the extension of treatment duration from 18 to 24 months and the new indications (glucocorticoid induced and male osteoporosis). We list alongside the results recorded in Greece.

Methods: Baseline characteristics of Greek participants in EFOS are juxtaposed with those of participants in ExFOS. Data regarding by sex analysis of the latter cohort (post-hoc analysis) is incorporated. Descriptive comparison of the Hellenic population of EFOS and ExFOS is attempted.

Results: ExFOS enrollment speed in Greece is 45% increased compared to EFOS. Enrollers are as elderly, exhibiting equally low bone density. Profile is somewhat different between sexes. As in EFOS, ExFOS patients complain of relatively frequent, severe back pain. Currently enrolled patients smoke more (male derived increase) but are more active (higher exercise rates and less need of arms assistance to rise). Noticeably, numerically fewer patients (especially in the female population) had fracture history, especially vertebral, compared to the Hellenic EFOS cohort. Approximately one in five patients, a fraction equivalent to that observed in EFOS, had no antiosteoporotic treatment whatsoever. A numeric decrease in calcitonin and an increase in bisphosphonates use, as prior antiresorptives, can be displayed.

Conclusions: Hellenic EFOS patients share similarities with female ExFOS patients but also have noticeable differences that may indicate a relative change towards prescription in less severely affected patients. Differences observed between male and female ExFOS TPTD users may reflect distinction in osteoporosis diagnosis and treatment for males. Data are interpreted in the context of an observational setting.

Article tools

My recent searches

No recent searches.